O'Shaughnessy Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$550K	Buy	4,488 +2,048	+84%	+$214K	﹤0.01%	1562
2026 Q1	$257K	Sell	2,440 -1,929	-44%	-$171K	﹤0.01%	1866
2025 Q4	$382K	Buy	+4,369	New	+$358K	﹤0.01%	1647
2024 Q4	–	Sell	-4,551	Closed	-$211K	–	2272
2024 Q3	$211K	Buy	+4,551	New	+$184K	﹤0.01%	1659
2021 Q4	–	Sell	-2,162	Closed	-$38K	–	2183
2021 Q3	$38K	Sell	2,162 -241	-10%	-$10.3K	﹤0.01%	1757
2021 Q2	$108K	Buy	2,403 +197	+9%	+$6.5K	﹤0.01%	1276
2021 Q1	$57K	Buy	+2,206	New	+$55.8K	﹤0.01%	1363

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

O'Shaughnessy Asset Management's PTGX Position: Q2 2026 in Review

O'Shaughnessy Asset Management increased its Protagonist Therapeutics (PTGX) stake by 84% in Q2 2026, buying an estimated $214K and bringing the position to 4,488 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

O'Shaughnessy Asset Management first reported a position in PTGX in Q1 2021 and has held it in 7 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

O'Shaughnessy Asset Management held 4,488 shares of Protagonist Therapeutics worth $550K as of Q2 2026.
O'Shaughnessy Asset Management bought 2,048 Protagonist Therapeutics shares in Q2 2026, an estimated $214K.
Protagonist Therapeutics made up ﹤0.01% of O'Shaughnessy Asset Management's portfolio in Q2 2026, its #1562 holding.
O'Shaughnessy Asset Management first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 7 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.